Contingencies and commitments - Noile-Immune Collaboration Agreement (Details) - License agreement - Noile Immune Biotech Inc. - USD ($) |
Aug. 26, 2019 |
Dec. 31, 2023 |
|---|---|---|
| Contingencies and commitments | ||
| Upfront license fees | $ 2,500,000 | |
| Maximum | ||
| Contingencies and commitments | ||
| Potential milestone payments | $ 312,000,000 |
| X | ||||||||||
- Definition Represents the amount of payments that the entity is required to make under the agreement, upon achievement of certain development and product milestones. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of upfront license fees paid. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|